The device called Mint, which would work with the company’s adaptive insulin dosing algorithm, is expected to debut in the ...
Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that near real-time real-world data on the iLet Bionic Pancreas is ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Johnson Fistel, PLLP is investigating whether Beta Bionics, Inc. (NASDAQ: BBNX) or certain of its executive officers violated federal securities laws. The investigation focuses on investors' losses ...
Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it expects to fully commercialize Mint by the end of the ...
Beta Bionics (NASDAQ:BBNX) Chief Financial Officer Stephen Feider said the company's first-quarter outperformance was ...
Diabetes management technology pioneer Beta Bionics has achieved another milestone, successfully amassing $100 million in its latest Series D equity funding round. The recent accomplishment surpasses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results